Medication Reconciliation in Hospitalized CKD Patients : A Quasi-Experimental Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

323 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-02-01

Study Completion Date

2023-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aimed to evaluate the impact of combining medication reconciliation with medication review on reducing medication discrepancies at discharge and all-cause readmissions among CKD patients, in comparison to a retrospective control group that received usual care, which may or may not have included medication reconciliation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Multi-Center Medication Reconciliation Quality Improvement Study

NCT01337063

Adverse Drug Events Medication Administered in Error

COMPLETED NA

Effectiveness of Pre-Consultation Medication Reconciliation Service in Reducing Unintentional Medication Discrepancies During Transition of Care From Hospital Discharge to Primary Care Setting

NCT03181906

Medication Administered in Error Medication Adherence

COMPLETED NA

Medication Intervention in Transitional Care to Optimize Outcomes & Costs for CKD & ESRD

NCT01459770

Chronic Kidney Disease End-Stage Renal Disease

COMPLETED NA

Effects of Pharmacist-led Medication Reconciliation Services on Geriatric Patients

NCT06610292

Geriatric Patients Medication Reconcilitation Upon Hospital Admission Medication Reconciliation At Discharge +1 more

COMPLETED NA

Using Novel Canadian Resources to Improve Medication Reconciliation at Discharge

NCT01179867

Medication Reconciliation Adverse Drug Events

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Kidney Disease(CKD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

This was a quasi-experimental trial

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention group

interventional group, in which patients received a supplemented medication reconciliation service.

Group Type EXPERIMENTAL

Medication reconciliation service

Intervention Type OTHER

Patients in the interventional group received medication reconciliation at admission and discharge in addition to continuous medication review during their admissions.

Retrospective control group in which patients received the usual care

A retrospective control group in which patients received the usual care that may or may not include medication reconciliation

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Medication reconciliation service

Patients in the interventional group received medication reconciliation at admission and discharge in addition to continuous medication review during their admissions.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult (18 years or older) admitted patients with CKD (stages 2-5 ), who were using at least three chronic medicines at home, and were hospitalized for at least 48 hours.

Exclusion Criteria

* Patients with kidney transplantation .
* Patients who have difficulties in responding to interviews and did not have family member or caregiver on behave.
* Patients who refused to provide a written informed consent.

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No